Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | BCR | P11274 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.39 |
| ▸ | TUBB | P07437 | 1/20 | 0.39 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11881437 | 0.95 | ALDH1A1 (0.46) | ALDH1A1CYP1A1CYP1B1PKMCYP3A4 | |
| SCHEMBL2852652 | 0.87 | FFAR4 (0.42) | ALDH1A1CYP1A1CYP1B1PKMCYP3A4 | |
| SCHEMBL28188557 | 0.87 | RAPGEF4 (0.43) | ALDH1A1CYP1A1CYP1B1PKMCYP3A4 | |
| SCHEMBL13584602 | 0.86 | MAPT (0.38) | ALDH1A1CYP1A1CYP1B1PKMCYP3A4 | |
| SCHEMBL18331985 | 0.86 | FFAR4 (0.41) | ALDH1A1CYP1A1CYP1B1PKMFFAR4 | |
| SCHEMBL19024616 | 0.86 | CYP3A4 (0.38) | ALDH1A1CYP1A1CYP1B1PKMCYP3A4 | |
| SCHEMBL31314383 | 0.86 | MAPT (0.38) | ALDH1A1CYP1A1CYP1B1PKMCYP3A4 | |
| 1,3,5-Trimethoxybenzene SCHEMBL2496933 | 0.85 | ALDH1A1 (0.65) | ALDH1A1CYP1A1CYP1B1PKMCYP3A4 | |
| SCHEMBL701972 | 0.81 | CNR1 (0.41) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL16829550 | 0.80 | PTGS1 (0.46) | ALDH1A1PTGS2ALOX5TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270762-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | SPRING MILL PHARMA, INC. | 2024-08-15 | — | — | US | disclosed |
| US-20240148744-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | ZOETIS LLC | 2024-05-09 | — | — | US | disclosed |
| EP-4347607-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117693511-A | Penicillin binding protein inhibitors | 维纳拓尔斯制药公司 | 2024-03-12 | — | — | CN | disclosed |
| EP-4291555-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | Celgene Corporation (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-116806218-A | Sulfonamide and its use for the treatment of parasitic helminth infections and diseases | 新基公司 | 2023-09-26 | — | — | CN | disclosed |
| WO-2022173727-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CELGENE CORPORATION (US) | 2022-08-18 | — | — | WO | disclosed |
| WO-2014207508-A1 | PYRIDYL COMPOUND SUITABLE FOR THE TREATMENT OF METABOLIC DISORDERS | Piramal Enterprises Limited (IN) | 2014-12-31 | — | — | WO | disclosed |
| EP-1648867-B1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON INC (US) | 2013-09-04 | — | — | EP | disclosed |
| US-8367828-B2 | PPAR active compounds | PLEXXIKON INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20050148659-A1 | Amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl compounds, a process and intermediates for their production, and pharmaceutical compositions containing them | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-07-07 | — | — | US | disclosed |
| WO-2005037780-A2 | AMIDOMETHYL-SUBSTITUTED 2-(4-SULFONILAMINO)-3-HIDROXY-3,4-DIHYDRO-2H-CHROMIUM-6-YL-DERIVATIVES AND DRUGS CONTAINING SAID COMPOUNDS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-04-28 | — | — | WO | disclosed |
| US-20050038246-A1 | PPAR active compounds | PLEXXIKON, INC. | 2005-02-17 | — | — | US | disclosed |
| WO-2005009958-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050004142-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2005-01-06 | — | — | US | disclosed |
| EP-1425284-A2 | FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003022852-A2 | FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-20 | — | — | WO | disclosed |
| EP-0038458-B1 | 4-HYDROXY-1,2-BENZISOTHIAZOL-3(2H)-ONE-1,1-DIOXIDE, THEIR SALTS, THEIR PREPARATION AND THEIR UTILIZATION | Dr. Karl Thomae GmbH (DE) | 1983-09-21 | — | — | EP | disclosed |
| US-4404230-A | ARTICIFIAL SWEETENERS | DR. KARL THOMAE GMBH (DE) | 1983-09-13 | — | — | US | disclosed |
| EP-0038458-A1 | 4-Hydroxy-1,2-benzisothiazol-3(2H)-one-1,1-dioxide, their salts, their preparation and their utilization | Dr. Karl Thomae GmbH (DE) | 1981-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038246-A1 | PPAR active compounds | PPARG, PPARD, PPARA | ALDH1A1 1171/4885CYP1A1 1121/4885CYP1B1 1212/4885 |
| US-20050004142-A1 | Chemical compounds | TIE1, KDR, TEK | ALDH1A1 906/4885CYP1A1 1654/4885CYP1B1 535/4885 |
| US-20240148744-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | ARSA, MRPS2, SULT2A1 | ALDH1A1 1470/4885CYP1A1 453/4885CYP1B1 439/4885 |
| US-20050148659-A1 | Amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl compounds, a process and intermediates for their production, and pharmaceutical compositions containing them | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP4B1, CYP3A4 | ALDH1A1 1020/4885CYP1A1 38/4885CYP1B1 41/4885 |
| US-20240270762-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | ALDH1A1 2794/4885CYP1A1 2708/4885CYP1B1 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.